Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
Fiche publication
Date publication
février 2019
Journal
Expert review of pharmacoeconomics & outcomes research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr LEPAGE Côme
Tous les auteurs :
Lacas B, Bouché O, Etienne PL, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon JP, Lepage C, Ducreux M, Borget I
Lien Pubmed
Résumé
This study compared the cost and quality of life (QoL) of 407 advanced colorectal cancer patients, randomly assigned to receive LV5FU2 followed by FOLFOX6 (sequential strategy) or FOLFOX6 followed by FOLFIRI (combination strategy).
Mots clés
Metastatic colorectal cancer, cost, irinotecan, oxaliplatin, quality of life, randomised trial
Référence
Expert Rev Pharmacoecon Outcomes Res. 2019 Feb 9;: